0
Your cart

Your cart is empty

Browse All Departments
  • All Departments
Price
  • R500 - R1,000 (1)
  • R1,000 - R2,500 (2)
  • R2,500 - R5,000 (2)
  • -
Status
Brand

Showing 1 - 5 of 5 matches in All Departments

Leading Pharmaceutical Innovation - How to Win the Life Science Race (Hardcover, 3rd ed. 2018): Oliver Gassmann, Alexander... Leading Pharmaceutical Innovation - How to Win the Life Science Race (Hardcover, 3rd ed. 2018)
Oliver Gassmann, Alexander Schuhmacher, Max Von Zedtwitz, Gerrit Reepmeyer
R2,637 Discovery Miles 26 370 Ships in 12 - 19 working days

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

Leading Pharmaceutical Innovation - Trends and Drivers for Growth in the Pharmaceutical Industry (Hardcover, 2nd ed. 2008):... Leading Pharmaceutical Innovation - Trends and Drivers for Growth in the Pharmaceutical Industry (Hardcover, 2nd ed. 2008)
Oliver Gassmann, Gerrit Reepmeyer, Maximilian Von Zedtwitz
R1,526 Discovery Miles 15 260 Ships in 10 - 15 working days

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.

UnCommoditized - Uncommon Ideas for Commoditized Markets (Hardcover): Saikat Dey, Gerrit Reepmeyer UnCommoditized - Uncommon Ideas for Commoditized Markets (Hardcover)
Saikat Dey, Gerrit Reepmeyer
R725 Discovery Miles 7 250 Ships in 12 - 19 working days
Risk-sharing in the Pharmaceutical Industry - The Case of Out-licensing (Paperback, 2006 ed.): Gerrit Reepmeyer Risk-sharing in the Pharmaceutical Industry - The Case of Out-licensing (Paperback, 2006 ed.)
Gerrit Reepmeyer
R2,975 Discovery Miles 29 750 Ships in 10 - 15 working days

The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year."

Leading Pharmaceutical Innovation - How to Win the Life Science Race (Paperback, Softcover reprint of the original 3rd ed.... Leading Pharmaceutical Innovation - How to Win the Life Science Race (Paperback, Softcover reprint of the original 3rd ed. 2018)
Oliver Gassmann, Alexander Schuhmacher, Max Von Zedtwitz, Gerrit Reepmeyer
R1,767 Discovery Miles 17 670 Ships in 10 - 15 working days

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

Free Delivery
Pinterest Twitter Facebook Google+
You may like...
Waterboy - Making Sense Of My Son's…
Glynis Horning Paperback R320 R295 Discovery Miles 2 950
Helene de Kock Keur 6
Helene Kock Paperback R290 R272 Discovery Miles 2 720
Advances in Longitudinal Data Methods in…
Nicholas Tsounis, Aspasia Vlachvei Hardcover R7,160 Discovery Miles 71 600
Die Ballade Van Robbie De Wee - En Ander…
Deon Meyer Paperback  (1)
R375 R352 Discovery Miles 3 520
Business Cycles in BRICS
Sergey Smirnov, Ataman Ozyildirim, … Hardcover R4,446 Discovery Miles 44 460
Claiming Our Callings - Toward a New…
Kaethe Schwehn, L.DeAne Lagerquist Hardcover R4,076 Discovery Miles 40 760
Amino Acids, Peptides and Proteins…
G. C. Barrett, Don T. Elmore, … Hardcover R10,923 Discovery Miles 109 230
Pediatric Endocrinology, An Issue of…
Robert Rapaport Hardcover R2,667 Discovery Miles 26 670
Engineering Textiles - Research…
Alexandr A. Berlin, Roman Joswik, … Paperback R2,628 Discovery Miles 26 280
The Craft of Ritual Studies
Ronald L. Grimes Hardcover R4,095 Discovery Miles 40 950

 

Partners